King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Labs have partnered to develop Saudi Arabia's first fully integrated, modular advanced therapy medicinal product (ATMP) manufacturing campus.
The new facility will be located at KFSHRC's main campus in Riyadh, Saudi Arabia and will serve as a critical milestone in advancing Vision 2030 and the National Biotechnology Strategy — two national initiatives aimed at transforming the country into a global hub for life sciences and biomanufacturing, with an end goal of becoming a global biotech hub by 2040.
The Germfree-partnered turnkey project — announced at the BIO International Convention 2025 — will fast track Saudi Arabia’s ability to manufacture cell and gene therapies locally, host international clinical trials, and attract leading pharma partnerships and scientific talent from around the world.
The ATMP manufacturing campus will be delivered as a fully CGMP-compliant, off-site built, modular solution, developed in strategic phases to support immediate clinical impact and long-term growth. The project will begin with the deployment of Germfree's BioGO Box single-module cleanroom solution, enabling early operator training, tech transfer, and R&D activities.
In parallel, a newly constructed facility will be built centrally on the KFSHRC campus to house prefabricated modular cleanroom clusters, providing 16 production suites, each designed for multi-modal CGT production supporting both clinical and commercial-scale manufacturing.
The plan is to reach full operational readiness within just 18 months after contract signing — roughly half the timeline of a conventional stick-built facility of comparable scope.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!